The nicotine replacement therapy market is mainly driven by increased smoking cessation programs, heightened health awareness, and the rising incidence of cancer due to ongoing tobacco use through cigarettes, pipes, cigars, and other forms in both developed and developing nations.

DelveInsight’s Nicotine Replacement Therapy Market Insights report provides the current and forecast market analysis, individual leading nicotine replacement therapy companies’ market shares, challenges, nicotine replacement therapy market drivers, barriers, trends, and key market nicotine replacement therapy companies in the market.

Key Takeaways from the Nicotine Replacement Therapy Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global nicotine replacement therapy market during the forecast period. 
• In the application segment of the nicotine replacement therapy market, the gums category had a significant revenue share in the year 2023.
• Notable nicotine replacement therapy companies such as Cipla Ltd., Johnson & Johnson Services, Inc., GLENMARK PHARMACEUTICALS LTD., Pfizer Inc., Rubicon Research Pvt. Ltd., Sparsha Pharma International Pvt Ltd., GSK plc, Philip Morris Products S.A., JB Pharma, PL Developments, Dr Reddy’s Laboratories Ltd., and Rusan Pharma Limited, and several others, are currently operating in the nicotine replacement therapy market.
• In July 2024, Haleon announced that it is set to divest its nicotine replacement therapy division outside the US to a subsidiary of India’s Dr. Reddy’s for £500 million ($632.55 million).
• In May 2024, Ventus Medical LTD declared that it had filed a UK Marketing Authorisation Application for ENHALE, an advanced smoking cessation and harm reduction product designed to offer tobacco users a safer option compared to both smoking and vaping.

To read more about the latest highlights related to the nicotine replacement therapy market, get a snapshot of the key highlights entailed in the Global Nicotine Replacement Therapy Market Report

Nicotine Replacement Therapies Overview

Nicotine replacement therapy is a method designed to help individuals quit smoking by providing a controlled dose of nicotine to reduce withdrawal symptoms and cravings. Nicotine Replacement Therapy products include options such as nicotine patches, gum, lozenges, nasal sprays, and inhalers. Nicotine Replacement Therapy products work by delivering nicotine in a less harmful way than smoking, helping to ease the transition from tobacco use to cessation. By gradually reducing nicotine levels, Nicotine Replacement Therapy can aid in the management of cravings and withdrawal symptoms, making the quitting process more manageable and increasing the likelihood of long-term success.

In addition to alleviating withdrawal symptoms, Nicotine Replacement Therapy can also help address the behavioral and psychological aspects of smoking addiction. Many smokers struggle with the habit of smoking and the associated routines, and NRT provides a way to break this cycle while still addressing the body’s need for nicotine. Combining NRT with behavioral support, such as counseling or support groups, can further enhance the chances of quitting successfully. Overall, Nicotine Replacement Therapy is a well-researched and effective tool for those looking to quit smoking, offering a safer alternative to traditional smoking methods.

Nicotine Replacement Therapy Market Insights 

In 2023, North America held the largest share of the nicotine replacement therapy market. This dominance is attributed to several key factors: an increasing number of individuals seeking to quit smoking, a rise in government initiatives and programs addressing the dangers of tobacco and promoting quitting strategies, high disposable incomes, advanced healthcare infrastructure, the presence of major industry players, and ongoing product development efforts. These factors are expected to drive the growth of the Nicotine Replacement Therapy market in the region from 2024 to 2030.

Additionally, the presence of prominent organizations promoting smoking cessation will further support market growth. For instance, the American Lung Association’s Freedom From Smoking® program, one of the most effective cessation programs in the country, aids individuals in quitting all tobacco products, including e-cigarettes and vaping devices. Such initiatives will enhance awareness of smoking cessation methods, including Nicotine Replacement Therapy, and boost demand for these therapies.

To know more about why North America is leading the market growth in the nicotine replacement therapy market, get a snapshot of the Nicotine Replacement Therapy Market Outlook 

Nicotine Replacement Therapy Market Dynamics

The nicotine replacement therapy market is a dynamic sector within the broader pharmaceutical and consumer health industries, driven by the growing global awareness of the health risks associated with smoking and the increasing demand for smoking cessation products. NRT products, such as nicotine patches, gum, lozenges, nasal sprays, and inhalers, are designed to help individuals reduce or quit their nicotine dependence by delivering controlled doses of nicotine to ease withdrawal symptoms. The market’s growth is influenced by various factors, including public health initiatives, regulatory changes, and evolving consumer preferences.

One of the key drivers of the Nicotine Replacement Therapy market is the rising global prevalence of smoking and the associated health risks, such as cardiovascular diseases and respiratory conditions. Governments and health organizations worldwide have implemented stringent regulations and anti-smoking campaigns, which have increased the demand for effective smoking cessation aids. Additionally, the growing awareness of the benefits of quitting smoking and the availability of various NRT options have contributed to the market’s expansion. The development of new and innovative NRT products that offer convenience, effectiveness, and reduced side effects is also fueling Nicotine Replacement Therapy market growth.

However, the Nicotine Replacement Therapy market faces several challenges, including competition from alternative smoking cessation methods, such as prescription medications and electronic cigarettes. The effectiveness of NRT products can vary among individuals, which sometimes leads to skepticism regarding their overall efficacy. Furthermore, the market is subject to regulatory scrutiny and approval processes, which can impact product availability and pricing. Manufacturers must navigate these challenges while continuing to innovate and address the diverse needs of consumers seeking to quit smoking.

Consumer preferences and market trends are shifting towards more personalized and integrated approaches to smoking cessation. This includes the incorporation of digital tools and mobile applications that support behavior modification and track progress. Companies are investing in research and development to create products that not only address nicotine dependence but also support behavioral change and long-term cessation success. As the market evolves, collaboration between healthcare providers, policymakers, and industry stakeholders will be crucial in advancing effective and accessible solutions for smoking cessation.

Get a sneak peek at the nicotine replacement therapy market dynamics @ Nicotine Replacement Therapy Market Dynamics Analysis

Nicotine Replacement Therapy Market Assessment

• Nicotine Replacement Therapy Market Segmentation
  • Nicotine Replacement Therapy Market Segmentation By Product Type: Gums, Patches, Lozenges, Nicotine Replacement Inhalers, and Others
  • Nicotine Replacement Therapy Market Segmentation By Type: OTC and Prescription
  • Nicotine Replacement Therapy Market Segmentation By Distribution Channel: Online and Offline
  • Nicotine Replacement Therapy Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the nicotine replacement therapy market are set to emerge as the trendsetter explore @ Nicotine Replacement Therapy Companies 

Table of Contents 

Interested in knowing the nicotine replacement therapy market by 2030? Click to get a snapshot of the Nicotine Replacement Therapy Market Trends

Related Reports

Nicotine Addiction Market

Nicotine Addiction Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key nicotine addiction companies including CTC Bio, Omeros, Antidote Therapeutics, Achieve Life Sciences, Respira Technologies, Mydecine, Astraea Therapeutics, Cessation Therapeutics, Alex Therapeutics, Embera Neuro Therapeutics, Novo Nordisk, Axsome Therapeutics, among others.

Nicotine Addiction Pipeline

Nicotine Addiction Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nicotine addiction companies including CTC Bio, Omeros, Antidote Therapeutics, Achieve Life Sciences, Respira Technologies, Mydecine, Astraea Therapeutics, Cessation Therapeutics, Alex Therapeutics, Embera Neuro Therapeutics, Novo Nordisk, Axsome Therapeutics, among others.

Smoking Cessation and Nicotine Addiction Market

Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key smoking cessation and nicotine addiction companies, including Achieve Life Sciences, NFL Biosciences SAS, Embera NeuroTherapeutics, Inc, Axsome Therapeutics, Currax Pharmaceuticals LLC, Omeros Corporation, Promentis Pharmaceuticals, Otsuka Pharmaceutical, among others.

Smoking Cessation and Nicotine Deaddiction Pipeline

Smoking Cessation and Nicotine Deaddiction Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key smoking cessation and nicotine deaddiction companies, including Achieve LifeSciences, NFL Biosciences, Axsome Therapeutics,  among others.

Nicotine Addiction Epidemiology Forecast

Nicotine Addiction Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted nicotine addiction epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

This upgrade reflects the shared vision and dedication of EOS’s global decentralized community, underscoring its commitment to pioneering blockchain innovation.

Bart Wyatt, CTO of the EOS Network Foundation, articulated the significance of this strategic development: “With the Spring 1.0 upgrade and the introduction of the Savanna consensus algorithm, we’re achieving something rare in the blockchain world: changing our core consensus algorithm. Very few Layer 1 blockchains have ever done this. I can think of only a handful—Ethereum being the most well known. In doing so, we’re standing on hallowed ground. By bringing EOS to an industry-leading 1-second finality, we’ve taken a massive leap forward, placing EOS at the forefront of blockchain innovation. This isn’t just a technical achievement—it’s about the EOS community taking full ownership.”

EOS Network has completed the transition to Antelope Spring 1.0, providing a non-contentious upgrade path. This process demonstrated the collaborative effort within the EOS community, involving extensive beta testing and a distributed activation, carried out by global block producers (BPs).

The Savanna consensus algorithm revolutionizes blockchain efficiency. By integrating advanced cryptographic techniques such as aggregate BLS signatures, Savanna ensures rapid, irreversible transactions, boosting both network security, scalability and unlocking new use cases in the blockchain industry.

Yves La Rose, CEO of the EOS Network Foundation: “Spring 1.0 marks a pivotal moment for the blockchain industry, introducing the Savanna consensus algorithm with 1-second Instant Finality via cutting-edge BLS cryptographic advancements. This upgrade offers unmatched transaction speed, reliability, and security, laying the foundation for next-generation decentralized applications to flourish. Achieving this was a collaborative feat involving internal teams and external partners, positioning EOS as one of the most technically advanced platforms.

As a transformative phase, Spring 1.0 enables new growth opportunities and adoption within the ecosystem. It unlocks unprecedented value for developers and anyone invested in the long-term potential of blockchain innovation. With proven technology and robust infrastructure, the future presents limitless possibilities as EOS propels the industry forward.”

As EOS Network forges ahead with Spring 1.0, it strengthens the foundation for continued innovation and community development. This significant leap in technology unlocks a vast array of new use cases, enhancing the EOS ecosystem. 

Follow EOS Network on Twitter or Telegram to stay up to date with the latest enhancements, updates and upgrades to the network. 

EOS Network Foundation
The EOS Network Foundation (ENF) was forged through a vision for a prosperous and decentralized future. Through our key stakeholder engagement, community programs, ecosystem funding, and support of an open technology ecosystem, the ENF is transforming Web3. Founded in 2021, the ENF is the hub for EOS Network, a leading open source platform with a suite of stable frameworks, tools, and libraries for blockchain deployments. Together, we are bringing innovations that our community builds and are committed to a stronger future for all.

Contact

Chief Communications Officer
Zack Gall
EOS Network Foundation
zack@eosn.foundation

For parents, this period can be both exciting and challenging, as they play a crucial role in supporting their children’s success. To help parents navigate the back-to-school time of the year effectively Nutrition expert Mia Syn partnered with The Vitamin Shoppe, Lunchables, and Farm Rich Snacks to provide actionable insights to help families navigate the school year with confidence, resilience, and well-being.

Here are Mia’s top picks to help make back-at-school a success.

Recommendations for parents looking to make mealtime easy and fun

A convenient and affordable option Mia always has on hand and shares with her friends and family is Lunchables.

For over 35 years, Lunchables have been parent-approved as the #1 brand for kid meal & snack combos. As school is back in full swing, Lunchables help make mealtime easy, fun and stress-free.

As a registered dietitian, Mia loves that Lunchables provide nutrients like protein, fiber, calcium and potassium—nutrients many kids are often deficient in. For example, the Turkey and Cheddar Crackers Stackers Snack Kits provide 13g of protein and include turkey slices, cheese and crackers.

Lunchables are available nationwide in conveniently packaged single-serve kits, serving as a delicious option for families any time of day including lunch time, after-school sports practice and more.

Instagram: https://www.instagram.com/lunchables/

TikTok: https://www.tiktok.com/@reallunchables

Facebook: https://www.facebook.com/Lunchables/

Tips for the entire family to help them reach health and wellness goals throughout the year

Solgar’s new Age Defying Nutrition line of supplements are powered by clinically-studied ingredients to help support joints, muscles, memory, hair, skin, and eyes.

Each serving of Solgar® Muscle Maintenance supports the preservation of lean muscle tissue, recovery after intense exercise, as well as muscle function and mass.

Additionally, Solgar® Joint Ease is formulated to support joint health, reduction in joint pain from physical activity, and a healthy inflammatory response.

You can find the full range of Solgar’s Age Defying Nutrition line at The Vitamin Shoppe stores, and on vitaminshoppe.com, the leading destination for health and wellness solutions.

#TheVitaminShoppe #Solgar

The go-to for after-school snacks

If you’re looking for wholesome snacks the kids will love AND make your life a little easier, turn to Farm Rich—one of America’s favorite frozen snacks brands. When it comes to after-school snacking, everyone loves America’s #1 Mozzarella Stick. They’re made with real mozzarella cheese and pack a lot of protein for extra brain fuel. Plus Farm Rich makes a variety of other delicious items kids crave.

To help motivate the kids at homework time, create a fun after-school snack board! Fill it with your favorite Farm Rich Snacks such as Mozz Sticks, Mozzarella Bites, Boneless Chicken Bites and Crispy Breaded Pickles. Then add some tasty dips and veggies for an extra healthy crunch. 

You can get more ideas like these at FarmRich.com.

Social Media: @FarmRichSnacks

For more information, visit NUTRITIONBYMIA.com

About D S Simon Media
The firm is well known as a leader in the satellite media tour industry and produces tours from its studio and multiple control rooms at its New York headquarters. Clients include top brands in healthcare, technology, travel, financial services, consumer goods, entertainment, retail and non-profits. Established in 1986 the firm has won more than 100 industry awards.

Dante Muccigrosso
Director of Media Integration & Client Reporting
E: dantem@dssimon.com
C: 973.524.0104

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5669c7f0-9fec-4cba-b27e-ca742a508e00

The UK Fast Growth Index identifies the fastest-growing businesses across seven nations and regions, highlighting their exceptional contributions to the UK economy. Collectively, the 350 businesses on this year’s index are generating over £12 billion ($16.1 billion) in revenue.

Former BBC TV host Omar Hamdi, Founder of Pay on Results PR, commented on the achievement:

“We are thrilled to be recognised as one of the 50 fastest-growing businesses in London. This acknowledgment is a testament to the hard work and dedication of our technical, client success, and content teams, and the thousands of clients, across 45 countries, whose stories we have shared with the media. We look forward to the awards evening, where we will celebrate this achievement alongside other remarkable businesses from across the UK.”

Image: Pay on Results PR featured in NASDAQ MarketSite, Times Square

Professor Dylan Jones-Evans, the founder of the UK Fast Growth Index, added:

“The businesses listed in this year’s UK Fast Growth Index represent the best of British entrepreneurship. Their collective contributions are driving significant economic growth, creating jobs, and shaping the future of the UK economy. We are proud to celebrate their success and look forward to revealing their place on the lists at the awards ceremony this November.”

The UK Fast Growth Awards ceremony promises to be a night of celebration, recognising businesses from across seven regions: London, the Midlands and the East of England, the North of England, Northern Ireland, Scotland, the South of England, and Wales. It will also honour the fastest-growing firms in twelve key sectors, acknowledging the incredible impact of these businesses on the UK’s economy.

About Pay on Results PR:

Pay on Results PR uses proprietary AI and tech to democratise access to the media for more than 4000 clients, across every industry, in 45 countries globally. Its tools include a PR LLM agent and the world’s only PR AI avatar chatbot, and are built around a proprietary community of over 200,000 media-focussed business owners and CEOs. The firm’s leadership and advisory board includes former KPMG USA national leader for strategic innovation Professor Sid Mohasseb, Shark Tank investor Kevin Harrington, and Emmy award-winning producer Brandon T. Adams.

About the Fast Growth Index:

The Fast Growth Index has been running in Wales for over 25 years, and its national roll-out is brought to you by the same team behind other notable programmes such as The Great British Entrepreneur Awards and The UK StartUp Awards. This initiative is more than just an annual index; it aims to build a community that supports, celebrates, and champions entrepreneurs at various stages. The index highlights the 50 fastest-growing businesses in seven nations and regions, based on revenue growth over a two-year period.

For more information about Pay on Results PR or to schedule an interview, please contact:

M. Richards

info@smallcappr.com

The Innovation Fellowship aims to cultivate a new generation of leaders in medical technology by providing intensive, hands-on experience in areas critical to the advancement of therapeutic medical devices. Throughout the 12-month program, participants will work closely with a best-in-class interdisciplinary team from clinical, engineering, and business.

Meet the Research Fellows
The inaugural cohort of fellows consists of two UT Southwestern fourth-year neurological surgery residents selected for their innovative ideas and dedication to the improvement of healthcare.

• Ryan Chiu, MD, intends to deepen his understanding of developing and implementing clinical trials for new biomedical devices.
• Keith George, MD, seeks to leverage his engineering background to enhance medical device innovation and gain comprehensive insight into the lifecycle of medical devices from conception to clinical implementation.

Empowering Clinicians 
Fellows will gain hands-on skills in critical areas including:

• Clinical Trial Management: Designing and executing trials, protocol submission, and trial enrollment.
• Federal Grants and Investor Engagement: Writing grant proposals and pitching to potential investors.
• FDA Regulatory Science: Navigating the FDA approval process for medical devices.
• Publication and Presentation: Preparing research for publication and presenting findings to peers and industry leaders.
• Intellectual Property: Develop an understanding of the technical, scientific, and legal aspects of patents 

“This fellowship brings in talented medical professionals to solve challenging healthcare needs while nurturing their entrepreneurial mindset. Fellows will be on the front lines of innovation with a team of like-minded healthcare leaders,” stated Dr. Navid Khodaparast, Ph.D., Co-founder & Chief Science Officer at Spark Biomedical.  
  
The Spark Biomedical Innovation Fellowship aims to set a new standard for medical research, nurturing talents that will aid in pushing the boundaries of medical science and patient care. This initiative reflects Spark Biomedical’s commitment to advancing health innovation.
  
About Spark Biomedical
Spark Biomedical, Inc. is a leading U.S.-based medical device developer committed to unlocking the potential of bioelectric medicine and bringing to market novel wearable neurostimulation treatment options in behavioral health, women’s health, hemostasis, pediatrics, and chronic pain.

Spark has received funding from federal institutions, such as the NIH and DoD, and continues to partner with private and academic institutes. Spark leverages its neuroscience and engineering expertise to empower healthcare providers and researchers with innovative, evidence-based tools designed to address complex care situations that exceed the capabilities of existing treatment options. Spark Biomedical is paving a better way forward for the future of patient care and medical technology. For more information, visit sparkbiomedical.com.

For more information, please contact Udim Obot at udim.obot@sparkbiomedical.com

###

 “While her presence as a board member will be greatly missed, we are thrilled to welcome Amanda in her new role” says Qlarant CEO Dr. Ron Forsythe, Jr. “The Qlarant Foundation has a profound impact on our community and has become a significate component of the overall organization. Having Amanda at the helm will continue to ensure its success.”

 From her previous role as Donor Relations Coordinator for Beebe Medical Foundation in Lewes, Delaware, Ms. Neal has experience executing multi-million dollar, capital fundraising campaigns; designing and implementing donor stewardship programs; and managing system-wide patient feedback programs. Her prior healthcare experience includes serving as the Director of Contracting and Procurement for United Medical Center in Washington, D.C.

 Ms. Neal has deployed her skills as a certified Six Sigma Green Belt, a Six Sigma Lean Professional, and a Change Management Specialist in multiple industries, including legal, information technology and finance. She has a bachelor’s in Communications from the University of Maryland and, prior to joining the Qlarant Foundation Board, Ms. Neal served on the Board of Associates for Kids Peace Foster Care in Baltimore, Maryland.

 The Qlarant Foundation is the philanthropic arm of Qlarant, Inc. It provides annually over $400k in grants to a variety of charities across Maryland and the District of Columbia. In 2024, 23 different groups received monetary support from the Foundation. To date, the Foundation has funded over $7 million in grants and continues to expand each year.  

 “The work done by our grantees is exceptional and often quite humbling,” notes Ms. Neal. “The dedication and commitment of each group is astounding. It’s quite a difficult decision to allocate funds each year—so many groups have impact on the community and clearly deserve our support”.

 As the current Vice Chair of the Qlarant Foundation, Lamont Thompson will serve as Chair until confirmed to officially fill the new vacancy in November. Lamont brings a wealth of experience and insight, and under his leadership, the board will continue to thrive and guide the Foundation to even greater heights.

 About Qlarant

 Qlarant is a not-for-profit, nationally respected leader in fighting fraud, waste, and abuse, improving program quality, and optimizing performance. The company uses subject matter experts and innovative data science and technology to help organizations see risks, solve problems, and seize opportunities. Qlarant provides customized solutions for state, federal and commercial industries across the nation. The Qlarant Foundation— the mission arm of the organization—has provided over $7 million in grants to charities throughout Maryland and the District of Columbia. Qlarant  has a 50-year record of accomplishment improving the performance of some of the Nation’s most important programs. Headquartered in Easton, MD, Qlarant has offices throughout the country and employs over 500 people. Qlarant is a five-time winner of the Best Places to Work award. For more information, visit www.qlarant.com or contact boosp@qlarant.com

Attachment

• The 2024 Qlarant Foundation Grant Program

Chris Williams brings over 20 years of experience in the biotechnology and life sciences sectors, with deep expertise in scaling bioprocessing technologies and driving operational excellence. Under his leadership, Cytek saw significant advancements, positioning the company as a leader in flow cytometry.

Prior to Cytek, Chris held key leadership roles in bioprocessing and engineering at Thermo Fisher Scientific and Bayer, where he spearheaded initiatives to enhance upstream and downstream processing technologies. His leadership in biomanufacturing and process development is a great complement to Culture Biosciences’ mission to revolutionize the bioprocessing industry through innovative, cloud-based solutions.

“We are thrilled to welcome Chris Williams to Culture Biosciences,” said Will Patrick, Co-Founder and Board Director. “Chris’s proven track record in commercializing equipment and his deep understanding of bioprocessing will be instrumental as we launch best-in-class solutions to our customers and partners.”

In his new role as CEO, Chris will focus on accelerating the company’s growth, expanding its portfolio of bioprocessing solutions, and further enhancing its cloud-based platform to meet the evolving needs of the biotech industry.

“I’m excited to join the talented team at Culture Biosciences and build on the strong foundation they’ve created,” said Chris Williams. “With the growing demand for scalable and flexible bioprocessing solutions, I’m confident that Culture Biosciences is well-positioned to lead the industry into the next era of innovation. I look forward to working closely with the team to drive the company’s growth and deliver transformative solutions to our customers.”

About Culture Biosciences

Culture Biosciences is transforming life science R&D with automated, scalable bioprocess development using cloud-connected bioreactors that connect data management and automated process control needed for experimental research. Culture offers complete upstream support for biopharma and synthetic biology innovations that includes dedicated suites for process analytics, cloud-native hardware and data-driven solutions for hybrid model development.

For more information visit: www.culture biosciences.com.   

“Slalom is a global company, and Allshore gives our customers access to customized delivery solutions that optimize speed, cost, and quality simultaneously. To be truly customer-obsessed means we must be able to consistently customize our solutions to each company’s situation to deliver the value they want and need. This means being agile, having deep knowledge of our customers’ businesses and how they serve their customers, and offering multiple options to shape their solutions,” said Brian Turner, Executive President of the Americas. “Slalom consultants excel in building products and delivering solutions that enable our customers to connect more deeply and best serve their customers. Allshore allows companies to reach their goals more quickly and successfully by using talent from around the globe.”

In LATAM, Slalom plans to hire more than 500 professionals through the next year to support Allshore customers who want help accelerating their growth and transformation, embracing emerging technology, and delivering initiatives faster and better.  

The company is encouraging engineers, senior engineers, and architects across software engineering, data engineering, platform engineering, and quality engineering in Mexico to apply at jobs.slalom.com. Slalom looks to hire those with specific experience in product engineering, cloud platforms (AWS, Azure, and GCP), D&A, and AI. To grow the Slalom team in Mexico, the company has hired Jose “Chema” Rancano, an experienced professional with over two decades of experience in consulting. He’s led teams at McKinsey and Accenture and lived in 13 cities across seven countries, providing him with a global perspective and professional experience.

“Great solutions come from smart and experienced consultants. Slalom is known globally for its culture of nurturing professionals who thrive in challenges and find joy in helping their clients solve complicated issues,” said Rancano. “Mexico’s talent is unique due to a combination of tenacity, innovation, and a strong work ethic deeply embedded in our culture. We have a certain ‘picardia’ or cleverness, a tendency to think differently, which translates into unique solutions and business models. Work in Mexico is not just a job; it’s a part of who we are, which means we bring our whole selves and cultural strengths to our work.”

Slalom has nearly 12,000 professional consultants across 10 countries and most recently opened offices in New Zealand, Netherlands, Australia, Germany, Ireland, and Japan. Slalom is an award-winning partner to 700 of the most innovative technology companies in the world, including AWS, Salesforce, Google Cloud, Microsoft, Snowflake, and Databricks. It has been recognized as a best company to work for by Fortune Magazine, Glassdoor, Forbes Magazine, and Human Rights Campaign. 

About Slalom
Slalom is a next-generation professional services company creating value at the intersection of business, technology, and humanity. With our fiercely human approach, we deeply understand our customers—and their customers—to deliver practical, end-to-end solutions that drive meaningful impact. Backed by over 700 technology partners, our nearly 12,000 team members in 10 countries and 49 offices help people and organizations dream bigger, move faster, and build better tomorrows for all. We’re honored to be consistently recognized as a great place to work, including being one of Fortune’s 100 Best Companies to Work For nine years running. Learn more at slalom.com.  

The new AI Assistant and Literature Monitoring in ReadCube — an award-winning leader in literature management and full-text document delivery — transform the way research teams access, organize, review and monitor scholarly literature by providing them with enhanced search capabilities while helping to significantly reduce time spent on manual work. ReadCube leverages the power of the Dimensions database of 145+ million publications to quickly and easily find what’s important.

Announcing the new features today in his keynote address at AI in Drug Discovery Xchange in San Francisco, ReadCube Co-founder and CEO Robert McGrath said the new tools help researchers focus on higher value work. According to data from Dimensions, the volume of published literature has grown about 30% over the past five years, putting pressure on research organizations to remain competitive while also ensuring their research teams are reading all articles relevant to their areas of focus.

“Literature monitoring and literature review are critically important for life sciences organizations, yet in practice the work remains highly manual and involves multiple teams and tools,” McGrath said.

“ReadCube works the way researchers do, letting them ask questions of the literature in their own words and get to an answer quickly. But unlike many other AI tools, our solution provides transparency and flexibility, enabling users to configure how AI is applied to each stage of their workflow. These AI enhancements, along with a host of enhanced search and library features, are designed to radically streamline many common research workflows,” he said.

ReadCube’s new AI Assistant and Literature Monitoring offer users the ability to:

• Integrate AI seamlessly with existing literature workflows
• Search all 145+ million publications in the Dimensions database, including full-text
• Transform natural language queries into hyper-specific searches through AI Assisted query builder
• Refine and narrow search results with smart AI filtering
• Receive highly relevant, AI-curated email notifications about new additions to ReadCube libraries.

ReadCube’s new AI Assistant enables researchers to analyze and summarize scientific articles. Researchers can query collections of articles within their library, and access contextual answers to complex questions within documents. With an improved user interface and real-time collaboration capabilities, the AI Assistant simplifies research tasks, enabling teams to work more efficiently and stay ahead in today’s fast-paced, innovation-driven environment, all in a private and secure environment.

Dr Daniel Hook, CEO of Digital Science, said: “Today’s announcement is a further step in realizing the potential of AI for the benefit of scientific research. It is our hope that our solutions will enable researchers in all disciplines and geographies to be more effective. In particular, for those in the fields of life sciences and pharmaceutical medicine, we believe that our tools can help to speed up discoveries that make a difference to health treatments and outcomes around the globe.”

Discover more at the ReadCube website.

About ReadCube

Part of Digital Science, ReadCube is a leader in scalable literature workflow solutions enhancing research-driven teams by transforming the way scholarly literature is managed, monitored and reviewed. Information overload and outdated workflows can impede progress and grind innovation to a halt. ReadCube’s adaptive AI-enhanced literature workflow solutions have helped millions of individuals and organizations get back to the breakthrough work that matters most. Follow ReadCube on LinkedIn.

About Digital Science

Digital Science is an AI-focused technology company providing innovative solutions to complex challenges faced by researchers, universities, funders, industry and publishers. We work in partnership to advance global research for the benefit of society. Through our brands – Altmetric, Dimensions, Figshare, IFI CLAIMS Patent Services, metaphacts, OntoChem, Overleaf, ReadCube, Scismic, Symplectic, and Writefull – we believe when we solve problems together, we drive progress for all. Visit digital-science.com and follow @digitalsci on X or on LinkedIn.

The Conavi shareholder approval of the Amalgamation was obtained at a special meeting of its shareholders (the “Conavi Special Meeting”) held today, September 26, 2024. 100% of the shares voted at the Conavi Special Meeting, were voted in favor of the proposal to approve the Amalgamation.

“We would like to thank our shareholders for their continued trust and support,” commented Tom Looby, Chief Executive Officer of Conavi. “This vote underscores their confidence in the Amalgamation with Titan and the exciting commercial path we have set for the future of our proprietary Novasight Hybrid System, the first technology platform to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries.”

“The completion of the Conavi shareholder approval is another important step in the process to close the Transaction” said Paul Cataford, Titan’s Interim CEO and Board Chairman. “Such a high approval for all shareholder resolutions is demonstrative of a high level of commitment and engagement for the shareholder base of a combined company”.

The completion of the Transaction remains subject to, among other things, satisfaction of the requirements in the TSX Venture Exchange’s (“TSXV”) conditional approval letter and the closing conditions described in the Amalgamation Agreement, as amended, including completion of Conavi’s concurrent private placement financing transaction (the “Concurrent Financing”) and the approval of Titan’s shareholders.

As previously announced on September 16 and September 19, 2024, independent proxy advisors, Institutional Shareholder Service (ISS) and Glass, Lewis & Co., have recommended that Titan’s shareholders vote FOR the Amalgamation.

Titan Shareholder Meeting

Titan will hold its annual general and special meeting of shareholders (the “Meeting”) on September 30, 2024, at 4:00 p.m. Eastern Time via audio webcast at https://web.lumiagm.com/449188251. Shareholders of record as of August 26, 2024 will have the ability to vote and to participate in the virtual meeting as explained in the joint management information circular in respect of the Transaction dated August 30, 2024 and which may be viewed at www.sedarplus.com (the “Circular”).

This vote is important. Shareholders will be asked to approve the Transaction. Closing of the Transaction will provide Shareholders the opportunity to participate in a new venture with strong institutional backing, newly invested cash, new management, new products, and new technology. Closing of the Transaction is conditional on the approval of all resolutions by Titan shareholders.

Titan shareholders are encouraged to review the Circular carefully and to vote in advance of the voting deadline of 4:00 p.m. Eastern Time on September 26, 2024.

Shareholder Questions

Shareholders are reminded that a webcast archive of the SHAREHOLDER QUESTION AND ANSWER SESSION, which took place on September 19, 2024, is accessible here.

Shareholders who have any questions about the Meeting, or require assistance with voting, may contact Shorecrest Group by telephone at 1-888-637-5789 or by email at contact@shorecrestgroup.com.

VOTE TODAY

Don’t Delay. Your vote matters no matter how many shares you own. Please vote by 4:00 pm Eastern Time TODAY.

About Titan Medical

Titan Medical Inc. (TSX: TMD; OTC: TMDIF), a medical technology company incorporated under the Business Corporations Act (Ontario) and headquartered in Toronto, Ontario, has developed an expansive patent portfolio related to the enhancement of robotic assisted surgery (RAS), including through a single access point, and is currently focused on evaluating new opportunities to further develop and license its intellectual property.

About Conavi Medical

Conavi Medical Inc. is a privately-owned company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid System is the first system to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China’s National Medical Products Administration, and Japan’s Ministry of Health, Labor and Welfare. For more information, visit http://www.conavi.com/.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Titan’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: the continued work of Titan and Conavi towards the completion of the Transaction, the completion of the Concurrent Financing and the expected date of the Meeting.

These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Titan’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Titan’s ability to retain key personnel; its ability to execute on its business plans and strategies; its ability to continue to license some or all its intellectual property to third parties and receive any material consideration; the receipt of required approvals from the TSXV and Titan’s shareholders in connection with the Transaction or change of listing or as to the success of Conavi’s Concurrent Financing (or the terms upon which such financing may be available if at all) and other factors listed in the “Risk Factors” section of Titan’s Annual Information Form for the fiscal year ended December 31, 2023 and in the Circular (each of which may be viewed at www.sedarplus.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.

Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Titan has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Titan cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Titan expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.

Contacts

Titan Medical Inc.
Chien Huang
Chief Financial Officer 
‎‎investors@titanmedicalinc.com

Conavi Medical Inc.
Stephen Kilmer
Investor Relations
(647) 872-4849     

###

521458567v.2